A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients.

ABSTRACT:

Background

Peanut allergy is a major public health problem that affects 1% of the population and has no effective therapy.

Objective

To examine the safety and efficacy of oral desensitization in peanut-allergic children in combination with a brief course of anti-IgE mAb (omalizumab [Xolair]).

Methods

We performed oral peanut desensitization in peanut-allergic children at high risk for developing significant peanut-induced allergic reactions. Omalizumab was administered before and during oral peanut desensitization.

Results

We enrolled 13 children (median age, 10 years), with a median peanut-specific IgE level of 229 kU(A)/L and a median total serum IgE level of 621 kU/L, who failed an initial double-blind placebo-controlled food challenge at peanut flour doses

SUBMITTER: Schneider LC 

PROVIDER: S-EPMC4405160 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature